

HAVE YOU OR SOMEONE YOU LOVE
BEEN DIAGNOSED WITH A CANCER
THAT HAS ALREADY SPREAD
(METASTATIC) NON-SMALL CELL
LUNG CANCER (NSCLC)?

HARMONi-3



About the HARMONi-3 Trial

Randomized: Patients are randomly assigned into different groups.

Double-blind: Neither the participants or the doctors know who is receiving which treatment.

Multiregional, phase 3 clinical trial of ivonescimab combined with chemotherapy versus pembrolizumab combined with chemotherapy.

For the first-line treatment (the patient has not been treated for lung cancer).

Diagnosed with metastatic (the cancer has spread), **non-small cell lung cancer (NSCLC)**.



HARMONi-3

Have You or Someone You Love Been Diagnosed with Metastatic Non-small Cell Lung Cancer (NSCLC)?

If yes, there is a phase 3 clinical trial called HARMONi-3 you may want to ask your doctor about.



What is the purpose of this clinical trial?

- The purpose of this phase 3 clinical trial is to measure overall survival (OS), progression-free survival (PFS) and safety of ivonescimab when combined with chemotherapy compared to pembrolizumab combined with chemotherapy. (OS: The amount of time after the start of a treatment that patients diagnosed are still alive. PFS: The length of time during and after the treatment that a patient lives with the disease and it does not get worse.)

What is the clinical trial drug, ivonescimab?

- Ivonescimab is an investigational treatment which may block two separate targets in the body; blocking these targets may decrease the cancer cells ability to live, grow, and spread.

Are you eligible for this clinical trial?

- You may be eligible if you have been diagnosed with metastatic NSCLC and you have not received any prior therapy for NSCLC in the metastatic setting. (You cannot have any genetic mutations which include EGFR, ALK, ROS1 or BRAF V600E.)
- Please talk with your doctor to determine if you are eligible.

If you are eligible, what is involved?

Your doctor can provide you with additional information but here are a few things to know:

- Once enrolled in the clinical trial, you will visit the clinic every three weeks for infusions.
- You will receive regular blood tests and scans of your tumor.
- You will be regularly asked about any side effects or safety concerns you have.

If you are in the clinical trial, will you receive ivonescimab?

- You will be randomly assigned to one of two treatment groups.
- Half the patients will be assigned to receive ivonescimab and chemotherapy and the other half will receive pembrolizumab and chemotherapy.

How are the drugs administered?

- Ivonescimab, chemotherapy, and pembrolizumab are administered by infusion (medication delivered into the body through the bloodstream instead of taking by mouth such as pills or liquid).

Ivonescimab is an investigational therapy that is not presently approved by any regulatory authority other than China's National Medical Products Administration (NMPA).

HARMONi-3



If you are interested in the
HARMONi-3 Clinical Trial,
please contact your doctor
for more information.

HARMONi-3



Learn more by visiting ClinicalTrials.gov
(Enter reference NCT05899608)

Or

Email medinfo@smmmtx.com

Ivonescimab is an investigational drug that is being
studied for its safety and effectiveness against
the current standard treatment.



Summit Therapeutics and the Summit Therapeutics logo are
trademarks of Summit Therapeutics Inc. Copyright 2025,
Summit Therapeutics Inc. All Rights Reserved.

MAT-SMT112-0141 v2

HARMONi-3Brochure/09.16.24